Ureteral Access Sheaths and Its Use in the Future: A Comprehensive Update Based on a Literature Review
- PMID: 36079058
- PMCID: PMC9456781
- DOI: 10.3390/jcm11175128
Ureteral Access Sheaths and Its Use in the Future: A Comprehensive Update Based on a Literature Review
Abstract
Ureteral access sheaths (UASs) are part of urologist's armamentarium when performing retrograde intrarenal surgery (RIRS). Recently, the world of RIRS has changed dramatically with the development of three game-changers: thulium fiber laser (TFL), smaller size single use digital flexible ureterosopes and intraoperative intrarenal pressure (IRP) measurement devices. We aimed to clarify the impact of UASs on IRP, complications and SFRs and put its indications in perspective of these three major technological improvements. A systematic review of the literature using the Medline, Scopus and Web of Science databases was performed by two authors and relevant studies were selected according to PRISMA guidelines. Recent studies showed that using a UAS lowers IRP and intrarenal temperature by increasing irrigation outflow during RIRS. Data on the impact of a UAS on SFRs, postoperative pain, risk of infectious complications, risk of ureteral strictures and risk of bladder recurrence of urothelial carcinoma after diagnostic RIRS were inconclusive. Prestenting for at least one week resulted in ureteral enlargement, while the influence of pre-operative administration of alpha-blockers was unclear. Since TFL, smaller single use digital ureteroscopes and devices with integrated pressure-measuring and aspiration technology seemed to increase SFRs and decrease pressure and temperature related complications, indications on the use of a UAS may decrease in the near future.
Keywords: nephrolithiasis; retrograde intrarenal surgery; systematic review; ureteral access sheath; ureteroscopy; urolithiasis.
Conflict of interest statement
Vincent De Coninck is a consultant for Axess Vision Technology, BD Bard and Coloplast, but has no specific conflict relevant to this work. Silvia Proietti is a consultant for Quanta System and Boston Scientific, but has no specific conflict relevant to this work. Olivier Traxer is a consultant for Coloplast, Karl Storz, Rocamed, Quanta Systems, Ambu, Boston Scientific, IPG medical, but has no specific conflict relevant to this work. Etienne Xavier Keller is a speaker and/or consultant for Coloplast, Olympus, Boston Scientific, Recordati, Debiopharm and Alnylam, and has no specific conflict of interest relevant to this work. All other authors have no conflict of interest to declare.
References
Publication types
LinkOut - more resources
Full Text Sources